BriaCell Therapeutics Corp. (BCTX)
After hours:
- Baystreet
Stocks in play: BriaCell Therapeutics Corp.
Announced U.S. FDA authorization of an Expanded Access Policy (EAP) for metastatic breast cancer (MBC) ...
- GlobeNewswire
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access policy will provide potential lifesaving Bria-IMT™ to those cancer patients in need beyond the scope of BriaCell’s pivotal Phase 3 clinical trial. PHILADELPHIA and VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company tha
- GlobeNewswire
BriaCell Therapeutics Announces Closing of $8.5 Million Offering
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering priced at-the-market under Nasdaq rules for 12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share, for gross
